Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

被引:36
作者
Braun, J
van der Heijde, D
机构
[1] Rheumazentrum Ruhrgebiet, D-44652 Herne, Germany
[2] Free Univ, Dept Gastroenterol & Rheumatol, Hosp Benjamin Franklin, Berlin, Germany
[3] Univ Maastricht, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
关键词
ankylosing spondylitis; anti TNF-alpha therapy; conventional and innovative treatment; psoriatic arthritis;
D O I
10.1517/13543784.12.7.1097
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-alpha agents currently available, infliximab (Remicade(R); Centocor), etanercept (Enbrel(R); Amgen) and adalimumab (Humira(TM); Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since no therapies with disease-controlling antirheumatic drugs are available for severely affected patients, especially with spinal disease. Thus, TNF blockers might even be considered as first-line immunosuppressive agents in patients with active AS and PsA who are not sufficiently treated by non-steroidal anti-inflammatory drugs and sulfasalazine, if peripheral arthritis is present. For infliximab, a dosage of 5 mg/kg at intervals between 6 and 12 weeks was necessary to constantly suppress disease activity; this is also a major aim of long-term treatment. No dose-finding studies have yet been performed. The standard dose of etanercept is 25 mg s.c. twice-weekly. No studies on adalimumab (standard RA dose 20-40 mg s.c. every 2 weeks) have yet been conducted in SpA. The efficacy of etanercept was first demonstrated in PSA and etanercept is now approved for this indication. A double-blind study has also been performed in AS, with similarly clearcut efficacy. There is preliminary evidence that both agents do also work in other SpA such as undifferentiated SpA. Infliximab has recently been approved for short-term treatment of severe uncontrolled AS; the approval for etanercept is pending. Studies should be performed to document the long-term efficacy of this treatment. There is hope that ankylosis might be preventable but it remains to be shown whether patients benefit from long-term anti-TNF therapy and whether radiological progression and ankylosis can be stopped. Severe adverse events have remained rare. Complicated infections including tuberculosis have been reported. Tuberculosis can be mostly prevented if patients are checked for previous contact with tuberculosis. Currently, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings.
引用
收藏
页码:1097 / 1109
页数:13
相关论文
共 135 条
[71]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104
[72]   Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate [J].
Kirby, B ;
Marsland, AM ;
Carmichael, AJ ;
Griffiths, CEM .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (01) :27-29
[73]   Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy:: one year follow up [J].
Kruithof, E ;
Van den Bosch, F ;
Baeten, D ;
Herssens, A ;
De Keyser, F ;
Mielants, H ;
Veys, EM .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (03) :207-212
[74]   Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis [J].
Kruithof, E ;
Kestelyn, P ;
Elewaut, C ;
Elewaut, D ;
Van den Bosch, F ;
Mielants, H ;
Veys, EM ;
De Keyser, F .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (05) :470-470
[75]   Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis [J].
Laloux, L ;
Voisin, MC ;
Allain, J ;
Martin, N ;
Kerboull, L ;
Chevalier, X ;
Claudepierre, P .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (04) :316-321
[76]  
Lautermann D, 2002, CLIN EXP RHEUMATOL, V20, pS11
[77]   Prognosis, course of disease, and treatment of the spondyloarthropathies [J].
Leirisalo-Repo, M .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (04) :737-+
[78]   Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo [J].
Leroux, JY ;
Guerassimov, A ;
Cartman, A ;
Delaunay, N ;
Webber, C ;
Rosenberg, LC ;
Banerjee, S ;
Poole, AR .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) :621-632
[79]   Is infliximab effective for induction of remission in patients with ulcerative colitis? [J].
Lichtenstein, GR .
INFLAMMATORY BOWEL DISEASES, 2001, 7 (02) :89-93
[80]  
Mackay K, 1998, ARTHRITIS RHEUM-US, V41, P2263, DOI 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.3.CO